Aquestive Therapeutics, Inc. Increase (Decrease) in Accounts and Other Receivables
Aquestive Therapeutics, Inc. (AQST) reported Increase (Decrease) in Accounts and Other Receivables of -$8.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-08-11
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-06-30 was $2.46M, a 82.55% increase year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was -$10.90M, a 448.23% decline year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was $5.96M.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was -$63.00K, a 101.70% decline year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2025 was $10.37M.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2024 was -$1.09M, a 135.60% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2023 was $3.07M.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2022 was -$7.35M, a 237.34% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$8.44M 10-Q · filed 2026-08-11 | -$2.48M derived: sum of 3 quarters · filed 2026-08-11 | -$2.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$10.90M 10-Q · filed 2026-05-13 | -$4.94M derived: sum of 2 quarters · filed 2026-05-13 | -$5.00M derived: sum of 3 quarters · filed 2026-05-13 | -$3.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.90M derived: sum of 2 quarters · filed 2026-03-04 | $7.24M derived: sum of 3 quarters · filed 2026-08-11 | $10.37M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.28M derived: sum of 2 quarters · filed 2026-08-11 | $4.41M 10-Q · filed 2025-11-05 | $2.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.48M 10-Q · filed 2026-08-11 | $2.15M derived: sum of 3 quarters · filed 2026-08-11 | $5.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.13M 10-Q · filed 2026-05-13 | $807.00K derived: sum of 2 quarters · filed 2026-05-13 | $4.52M derived: sum of 3 quarters · filed 2026-05-13 | $2.18M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.39M derived: sum of 2 quarters · filed 2026-03-04 | -$947.00K derived: sum of 3 quarters · filed 2026-03-04 | -$1.09M 10-K · filed 2026-03-04 |
| 2024-09-30 | $3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.38M derived: sum of 2 quarters · filed 2025-11-05 | $1.23M 10-Q · filed 2025-11-05 | $1.12M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$2.49M 10-Q · filed 2025-08-11 | -$2.59M derived: sum of 3 quarters · filed 2025-08-11 | -$4.14M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$147.00K 10-Q · filed 2025-05-12 | -$251.00K derived: sum of 2 quarters · filed 2025-05-12 | -$1.80M derived: sum of 3 quarters · filed 2025-05-12 | $709.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$1.66M derived: sum of 2 quarters · filed 2025-03-05 | $856.00K derived: sum of 3 quarters · filed 2025-03-05 | $3.07M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $960.00K derived: sum of 2 quarters · filed 2024-11-04 | $3.18M 10-Q · filed 2024-11-04 | -$2.92M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.73M 10-Q · filed 2024-08-06 | -$1.37M derived: sum of 3 quarters · filed 2024-08-06 | -$9.57M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.22M 10-Q · filed 2024-05-07 | -$3.88M derived: sum of 2 quarters · filed 2024-05-07 | -$12.08M derived: sum of 3 quarters · filed 2024-05-07 | -$12.81M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$14.30M derived: sum of 2 quarters · filed 2024-03-05 | -$15.03M derived: sum of 3 quarters · filed 2024-03-05 | -$7.35M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$8.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$8.94M derived: sum of 2 quarters · filed 2023-11-06 | -$1.26M 10-Q · filed 2023-11-06 | -$2.63M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$729.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $6.95M 10-Q · filed 2023-08-07 | $5.58M derived: sum of 3 quarters · filed 2023-08-07 | $6.91M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $7.68M 10-Q · filed 2023-05-02 | $6.30M derived: sum of 2 quarters · filed 2023-05-02 | $7.64M derived: sum of 3 quarters · filed 2023-05-02 | $9.66M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | -$1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$39.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.98M derived: sum of 3 quarters · filed 2023-03-31 | $5.35M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $3.35M derived: sum of 2 quarters · filed 2022-11-01 | $6.73M 10-Q · filed 2022-11-01 | $5.63M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $5.39M 10-Q · filed 2022-08-02 | $4.30M derived: sum of 3 quarters · filed 2022-08-02 | -$429.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $3.37M 10-Q · filed 2022-05-04 | $2.28M derived: sum of 2 quarters · filed 2022-05-04 | -$2.45M derived: sum of 3 quarters · filed 2022-05-04 | $937.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$5.82M derived: sum of 2 quarters · filed 2022-03-08 | -$2.44M derived: sum of 3 quarters · filed 2022-03-08 | -$6.17M 10-K · filed 2022-03-08 |
| 2020-09-30 | -$4.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$1.34M derived: sum of 2 quarters · filed 2021-11-02 | -$5.08M 10-Q · filed 2021-11-02 | -$2.15M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$354.00K 10-Q · filed 2021-08-03 | $2.57M derived: sum of 3 quarters · filed 2021-08-03 | $2.78M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | -$3.74M 10-Q · filed 2021-05-04 | -$810.00K derived: sum of 2 quarters · filed 2021-05-04 | -$607.00K derived: sum of 3 quarters · filed 2021-05-04 | $2.11M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $3.13M derived: sum of 2 quarters · filed 2021-03-09 | $5.85M derived: sum of 3 quarters · filed 2021-03-09 | $6.82M 10-K · filed 2021-03-09 |
| 2019-09-30 | $203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.92M derived: sum of 2 quarters · filed 2020-11-04 | $3.89M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $3.68M 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $963.00K 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $409.00K 10-K · filed 2020-03-11 | |||
| 2018-06-30 | -$2.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $481.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $3.30M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | -$4.69M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |